116289-64-6

Basic information

• Product Name: 3-(3-METHOXY-PHENOXY)-PHENYLAMINE
• Synonyms: 3-(3-METHOXY-PHENOXY)-PHENYLAMINE;3-(3-methoxyphenoxy)aniline
• CAS NO: 116289-64-6
• Molecular Formula: C₁₃H₁₃NO₂
• Molecular Weight: 215.25
• Mol File: 116289-64-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(3-METHOXY-PHENOXY)-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-METHOXY-PHENOXY)-PHENYLAMINE(116289-64-6)
• EPA Substance Registry System: 3-(3-METHOXY-PHENOXY)-PHENYLAMINE(116289-64-6)

Safety Data

• Hazardous Substances Data: 116289-64-6(Hazardous Substances Data)

Upstream product

• 107622-64-0 1-methoxy-3-(3-nitro-phenoxy)-benzene 
• 554-84-7 meta-nitrophenol 
• 766-85-8 3-methoxy-1-iodobenzene 
• 591-27-5 m-Hydroxyaniline 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 150-19-6 O-methylresorcine 
• 2398-37-0 3-methoxyphenyl bromide 

Relevant articles and documents

INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF

Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

Orthogonal Cu- and Pd-based catalyst systems for the O- and N-arylation of aminophenols

O- or N-arylated aminophenol products constitute a common structural motif in various potentially useful therapeutic agents and/or drug candidates. We have developed a complementary set of Cu- and Pd-based catalyst systems for the selective O- and N-arylation of unprotected aminophenols using aryl halides. Selective O-arylation of 3- and 4-aminophenols is achieved with copper-catalyzed methods employing picolinic acid or CyDMEDA, trans-N,N′-dimethyl-1,2- cyclohexanediamine, respectively, as the ligand. The selective formation of N-arylated products of 3- and 4-aminophenols can be obtained with BrettPhos precatalyst, a biarylmonophosphine-based palladium catalyst. 2-Aminophenol can be selectively N-arylated with CuI, although no system for the selective O-arylation could be found. Coupling partners with diverse electronic properties and a variety of functional groups can be selectively transformed under these conditions.

4-Substituted anilides as selective melatonin MT2 receptor agonists

A series of 4-substituted anilides with human melatonergic affinity is reported. Butyramides 26, 39, 42, 52, 57, and 58 all demonstrated subnanomolar MT2 binding affinity and MT2 selectivity of at least 70-fold over the MT1 receptor. Compound 26 demonstrated full agonism at the MT2 receptor.